Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABR-SYNC: Stereotactic Ablative Radiotherapy for Oligometastases and Synchronous Primary Tumor
NCT05717166Phase 3Recruiting
- Start
- Oct 2023
- Primary completion
- Apr 2029
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in tumor (2 arms). Primary endpoint: Overall Survival at 6 years. Started Oct 2023; status: recruiting.
02
Conditions
tumor
Beyond the preview
Go deeper on NCT05717166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05717166.